Evidence map›Paper›PMID 37124417›Full record

ArticleiScience2023

Saturation time of exposure interval for cross-neutralization response to SARS-CoV-2: Implications for vaccine dose interval.

Sho Miyamoto, Yudai Kuroda, Takayuki Kanno, Akira Ueno, Nozomi Shiwa-Sudo, Naoko Iwata-Yoshikawa, Yusuke Sakai, Noriyo Nagata, Takeshi Arashiro, Akira Ainai and 12 more

Abstract read
In one paragraph

Article in iScience, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.

0numbers the graph read from it
0cells of the map it votes in
3citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

3 citing papers in PubMed.

  1. Article
  2. Article
  3. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

22 authors.

Sho MiyamotoDepartment of Pathology, National Institute of Infectious Diseases, Tokyo 162-8640, Japan.
Yudai KurodaDepartment of Veterinary Science, National Institute of Infectious Diseases, Tokyo 162-8640, Japan.
Takayuki KannoDepartment of Pathology, National Institute of Infectious Diseases, Tokyo 162-8640, Japan.
Akira UenoDepartment of Pathology, National Institute of Infectious Diseases, Tokyo 162-8640, Japan.
Nozomi Shiwa-SudoDepartment of Pathology, National Institute of Infectious Diseases, Tokyo 162-8640, Japan.
Naoko Iwata-YoshikawaDepartment of Pathology, National Institute of Infectious Diseases, Tokyo 162-8640, Japan.
Yusuke SakaiDepartment of Pathology, National Institute of Infectious Diseases, Tokyo 162-8640, Japan.
Noriyo NagataDepartment of Pathology, National Institute of Infectious Diseases, Tokyo 162-8640, Japan.
Takeshi ArashiroDepartment of Pathology, National Institute of Infectious Diseases, Tokyo 162-8640, Japan.
Akira AinaiDepartment of Pathology, National Institute of Infectious Diseases, Tokyo 162-8640, Japan.
Saya MoriyamaResearch Center for Drug and Vaccine Development, National Institute of Infectious Diseases, Tokyo 162-8640, Japan.
Noriko KishidaCenter for Influenza and Respiratory Virus Research, National Institute of Infectious Diseases, Tokyo 208-0011, Japan.
Shinji WatanabeCenter for Influenza and Respiratory Virus Research, National Institute of Infectious Diseases, Tokyo 208-0011, Japan.
Kiyoko NojimaDepartment of Safety Research on Blood and Biological Products, National Institute of Infectious Diseases, Tokyo 208-0011, Japan.
Yohei SekiDepartment of Safety Research on Blood and Biological Products, National Institute of Infectious Diseases, Tokyo 208-0011, Japan.
Takuo MizukamiDepartment of Safety Research on Blood and Biological Products, National Institute of Infectious Diseases, Tokyo 208-0011, Japan.
Hideki HasegawaCenter for Influenza and Respiratory Virus Research, National Institute of Infectious Diseases, Tokyo 208-0011, Japan.
Hideki EbiharaDepartment of Virology I, National Institute of Infectious Diseases, Tokyo 162-8640, Japan.
Shuetsu FukushiDepartment of Virology I, National Institute of Infectious Diseases, Tokyo 162-8640, Japan.
Yoshimasa TakahashiResearch Center for Drug and Vaccine Development, National Institute of Infectious Diseases, Tokyo 162-8640, Japan.
Ken MaedaDepartment of Veterinary Science, National Institute of Infectious Diseases, Tokyo 162-8640, Japan.
Tadaki SuzukiDepartment of Pathology, National Institute of Infectious Diseases, Tokyo 162-8640, Japan.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Evaluating the serum cross-neutralization responses after breakthrough infection with various SARS-CoV-2 variants provides valuable insight for developing variant-proof COVID-19 booster vaccines. However, fairly comparing the impact of breakthrough infections with distinct epidemic timing on cross-neutralization responses, influenced by the exposure interval between vaccination and infection, is challenging. To compare the impact of pre-Omicron to Omicron breakthrough infection, we estimated the effects on cross-neutralizing responses by the exposure interval using Bayesian hierarchical modeling. The saturation time required to generate saturated cross-neutralization responses differed by variant, with variants more antigenically distant from the ancestral strain requiring longer intervals of 2-4 months. The breadths of saturated cross-neutralization responses to Omicron lineages were comparable in pre-Omicron and Omicron breakthrough infections. Our results highlight the importance of vaccine dosage intervals of 4 months or longer, regardless of the antigenicity of the exposed antigen, to maximize the breadth of serum cross-neutralization covering SARS-CoV-2 Omicron lineages.

Indexed as

Immune responseImmune systemImmunityVirology

Identifiers

PMID37124417
PMCPMC10114312

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.